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Abstract
Background: -catenin mutations that constitutively activate the canonical Wnt signaling have been observed in a
subset of hepatocellular carcinomas (HCCs). These mutations are associated with chromosomal stability, low histological
grade, low tumor invasion and better patient survival. We hypothesized that canonical Wnt signaling is selectively
activated in well-differentiated, but repressed in poorly differentiated HCCs. To this aim, we characterized differentiation
status of HCC cell lines and compared their expression status of Wnt pathway genes, and explored their activity of
canonical Wnt signaling.
Results: We classified human HCC cell lines into "well-differentiated" and "poorly differentiated" subtypes, based on the
expression of hepatocyte lineage, epithelial and mesenchymal markers. Poorly differentiated cell lines lost epithelial and
hepatocyte lineage markers, and overexpressed mesenchymal markers. Also, they were highly motile and invasive. We
compared the expression of 45 Wnt pathway genes between two subtypes. TCF1 and TCF4 factors, and LRP5 and LRP6
co-receptors were ubiquitously expressed. Likewise, six Frizzled receptors, and canonical Wnt3 ligand were expressed
in both subtypes. In contrast, canonical ligand Wnt8b and noncanonical ligands Wnt4, Wnt5a, Wnt5b and Wnt7b were
expressed selectively in well- and poorly differentiated cell lines, respectively. Canonical Wnt signaling activity, as tested
by a TCF reporter assay was detected in 80% of well-differentiated, contrary to 14% of poorly differentiated cell lines.
TCF activity generated by ectopic mutant -catenin was weak in poorly differentiated SNU449 cell line, suggesting a
repressive mechanism. We tested Wnt5a as a candidate antagonist. It strongly inhibited canonical Wnt signaling that is
activated by mutant -catenin in HCC cell lines.
Conclusion: Differential expression of Wnt ligands in HCC cells is associated with selective activation of canonical Wnt
signaling in well-differentiated, and its repression in poorly differentiated cell lines. One potential mechanism of
repression involved Wnt5a, acting as an antagonist of canonical Wnt signaling. Our observations support the hypothesis
that Wnt pathway is selectively activated or repressed depending on differentiation status of HCC cells. We propose
that canonical and noncanonical Wnt pathways have complementary roles in HCC, where the canonical signaling
contributes to tumor initiation, and noncanonical signaling to tumor progression.
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Background
Hepatocellular carcinoma (HCC) is an epithelial cancer
that originates from hepatocytes or their progenitors. It is
the fifth most frequent neoplasm worldwide (>500,000
deaths/year), and its incidence is steadily increasing in the
West [1]. Hepatocellular carcinoma is graded into four
stages as well-differentiated, moderately differentiated,
poorly differentiated and undifferentiated tumors, respec-
tively. HCC arises as a very well differentiated cancer and
proliferates with a stepwise process of dedifferentiation.
Indeed, well-differentiated histology is exclusively seen in
early stage and is rare in advanced HCC. Well-differenti-
ated and moderately differentiated HCC cells are morpho-
logically similar to hepatocytes, and are distinguished
only by their smaller size and architectural organization as
irregular trabecular or pseudoglandular patterns. In con-
trast, poorly differentiated and undifferentiated HCC cells
are characterized with scanty cytoplasms and pleomor-
phism [2]. Like in other epithelial tumors, in HCC the
progenitors evolve during tumor progression and become
more and more autonomous. In this process, the tumor
cells change their morphology and behavior; they loose
cuboidal shape and polarity, and become more independ-
ent from neighboring tissues. Finally, they acquire the
capacity to invade the underlying tissue and form distant
metastases. These morphological changes are usually
associated with progressive loss of biochemical and mor-
phological features of hepatocytes, hence the process is
qualified as "dedifferentiation" [3]. Portal venous inva-
sion is significantly associated with poorly differentiated
and undifferentiated HCCs and the tumor invasiveness is
the most crucial factor in determining the long-term out-
come for the patient [4].
Molecular changes involved in HCC dedifferentiation and
invasiveness are known only partially. Epithelial markers
such as hepatocyte nuclear factors and E-cadherin were
reported to be down-regulated in HCC [3,5] and their loss
is closely related to tumor invasion and metastasis [5]. In
contrast, mesenchymal cell markers such as snail [6], twist
[7] and vimentin [8] display positive correlation with
HCC invasiveness and/or metastasis. These changes have
been considered to represent the epithelial-mesenchymal
transition (EMT) in HCC, based on in vitro studies [9-15].
Hepatocyte nuclear factor-4 (Hnf-4) is essential for
morphological and functional differentiation of hepato-
cytes [16,17], and its expression is downregulated during
HCC progression in mice [18]. HCC dedifferentiation
process is associated with a progressive accumulation of
genomic changes including chromosomal gains and
losses, as well as p53 mutations [19]. A rare exception to
this picture is the status of the CTNNB1 gene that encodes
-catenin, a key component of the Wnt/-catenin (canon-
ical Wnt) signaling pathway.
Independent studies showed that -catenin mutations are
associated with a subset of low grade (well-differentiated)
HCCs with a favorable prognosis and chromosome stabil-
ity [20-25]. Among 366 unifocal HCCs studied by Hsu et
al. [20], -catenin mutations were associated with grade I
histogoly. Another study with similarly high number of
tumors (n = 372) also indicated that mutant nuclear -cat-
enin correlated positively with non-invasive tumor and
inversely with portal vein tumor thrombi [23]. In addi-
tion,  -catenin mutations were associated with signifi-
cantly better 5-year patient survival in these large cohorts.
Direct study of canonical Wnt signaling activity in primary
tumors is not possible. However, this can be studied indi-
rectly by using target genes [22]. Using glutamine syn-
thetase (encoded by canonical Wnt signaling target GLUL
gene) as a sensitive and specific marker, Audard et al. [22]
showed that 36% HCCs displayed canonical Wnt activa-
tion. These tumors exhibited significant features associ-
ated with well-differentiated morphology. The association
of  -catenin mutation and nuclear translocation with
well-differentiated tumor grade was also reported during
hepatocellular carcinogenesis, using several transgenic
mouse models [26]. Activation of -catenin was most fre-
quent in liver tumors from c-myc and c-myc/TGF-1
transgenic mice. However, it was very rare in faster grow-
ing and histologically more aggressive HCCs developed in
c-myc/TGF- mice. Taken together, these studies suggest
that nuclear translocation of -catenin and activation of
canonical Wnt signaling are early events in liver carcino-
genesis, mostly affecting well-differentiated HCCs.
Mutations of -catenin gene initially identified in colorec-
tal cancers, cause constitutive activation of canonical Wnt
signaling, as a result of aberrant -catenin protein accu-
mulation. Inactivating mutations of APC gene in colorec-
tal cancer and AXIN1 in HCC also activate canonical Wnt
signaling by the same mechanism. Therefore, tumors dis-
playing -catenin, APC or AXIN1 mutation are considered
to display active or constitutive canonical Wnt signaling
[27] Activation of canonical Wnt signaling appears to be a
common event for colorectal cancer, as opposed to HCC
with mutations limited to a subset of these cancers. Inter-
estingly, transgenic mice expressing oncogenic -catenin
in hepatocytes develop only hepatomegaly [28,29], in
contrast to intestinal polyposis and microadenoma when
expressed in intestinal cells [30].
Taken together, published data indicate that Wnt pathway
and -catenin mutations may play a complex role in HCC.
Close association of -catenin mutation with low tumor
grade suggests that canonical Wnt signaling has a dual role
in HCC cells, depending on their differentiation state. As
an initial attempt to characterize differentiation-depend-
ent functions of Wnt pathway and canonical Wnt signal-
ing in HCC, we used a panel of HCC-derived cell lines. WeMolecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
Page 3 of 20
(page number not for citation purposes)
first performed gene expression and in vitro cell migration
analyses to classify HCC cell lines into two distinct sub-
types. The first subtype that we named here as "well-differ-
entiated" was formed by epithelial cell lines with limited
motility and invasiveness. Mesenchymal-like cell lines
that have lost their epithelial-, hepatocyte-like features
clustered into a second subtype named as "poorly differ-
entiated". Next, we compared these two subtypes for the
expression of 45 Wnt pathway genes, as well as for the
activity of canonical Wnt signaling. Our findings provided
evidence for the constitutive activation of canonical Wnt
signaling in well-differentiated, but not in poorly differen-
tiated cell lines. We also report the upregulation canonical
Wnt3 ligand in the majority of HCC cell lines. Canonical
Wnt8b was selectively expressed in well-differentiated cell
lines. In contrast, noncanonical Wnt4, Wnt5a, Wnt5b and
Wnt7b ligands were expressed selectively in poorly differ-
entiated HCC cell lines. In addition, ectopic expression of
noncanonical Wnt5a inhibited canonical Wnt signaling
in two different cell lines. Our findings support the differ-
ential involvement of canonical and noncanonical Wnt
signaling in HCC, depending on tumor cell differentia-
tion state.
Results
Classification of hepatocellular carcinoma cell lines into 
"well-differentiated" and "poorly differentiated" subtypes
Fuchs et al. [12] have recently classified HCC cell lines
into "epithelial" and "mesenchymal" types based on E-
cadherin and vimentin expression. We performed a simi-
lar analysis using our cell line panel. Initially, we analyzed
15 cell lines (Figure 1). The expression of -fetoprotein
(AFP) was limited to six cell lines (Huh7, Hep40, HepG2,
Hep3B, Hep3B-TR, PLC/PRF/5); the other cell lines being
either not expressing (SNU182, SNU387, SNU398,
SNU423, SNU449, SK-Hep1, Mahlavu, FOCUS) or
weakly expressing (SNU475). All AFP-positive (AFP+) cell
lines also expressed E-cadherin, whereas only 3/9 (33%)
of AFP- cell lines expressed this epithelial marker. Mesen-
chymal cell markers including vimentin, slug, snail, twist-
1 and twist-2 were also positive in most AFP- cell lines.
These markers also displayed weakly positive expression
in some AFP+ cell lines. For confirmation, we performed
immunocytochemical analysis of vimentin protein
expression in five AFP+ and five AFP- cell lines (Figure 2).
We observed strong and homogenous immunostaining
with all five AFP- cell lines. In contrast AFP+ cell lines were
either negative or displayed heterogeneously positive
immunoreactivity. These findings suggested that all AFP+
HCC cell lines were epithelial-like based on E-cadherin
expression, but they also expressed some mesenchymal
cell markers at variable degrees. In contrast, AFP- cell lines
were usually negative for E-cadherin, and most of them
were strongly positive for mesenchymal cell markers. The
expression patterns of these mesenchymal markers
showed marked heterogeneity. For example, SNU182 was
positive for all five markers tested, whereas FOCUS was
positive only for vimentin expression.
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell lines Figure 1
Expression analysis of a-fetoprotein (AFP), E-cadherin and five mesenchymal cell markers in HCC cell lines. 
Total RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH was used as a con-
trol for expression analyses shown here and in figures 4 to 7.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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We selected four AFP+, and seven AFP- cell lines for fur-
ther analysis. HNF-4 and its downstream target HNF-1
are best known hepatocyte-associated epithelial cell mark-
ers [3]. These two genes that are involved in liver develop-
ment and hepatocyte specification have previously been
identified as specific markers for HCC cells with well-dif-
ferentiated function and morphology [31]. The expression
of these HNFs displayed perfect correlation with the
expression of AFP (Figure 3a): four AFP+ cell lines (Huh7,
Hep3B, HepG2, Hep40) were also highly positive for both
HNF-4 and HNF-1. In contrast, seven AFP- cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) did not express these factors. SNU449,
another AFP- cell line displayed only weak HNF-4
expression. Epithelial cells including hepatocytes show
low motility, in contrast to mesenchymal cells that display
high motility and invasive behavior. To test whether epi-
thelial and mesenchymal gene expression patterns of
HCC cells correlated with their in vitro motility, we used
wound-healing assay. After 24 hours of wounding, AFP-
HCC cells (Mahlavu, SNU449, SNU475, SNU182) moved
through the wound, whereas AFP+ HCC cells (Huh7,
Hep3B, Hep G2, Hep40) cells did not (Figure 3b; Hep40
and SNU182 data not shown). A quantitative analysis of
this data confirmed that poorly differentiated cell lines
display higher motility (Figure 3c).
Based on expression analysis, together with in vitro motil-
ity and previously published invasiveness data, we classi-
fied our panel of HCC cell lines into two subtypes (Table
1). We qualified HepG2, Huh7, Hep3B and Hep40 as
"well-differentiated" HCC cell lines, because they express
AFP, E-cadherin, HNF-4 and HNF-1, and they display
low motility and/or low invasiveness. Most of these fea-
tures are confined to "well-differentiated" HCC tumors
([2,18,32,33]. We qualified the remaining seven cell lines
(SNU398, SNU475, SNU449, SNU387, FOCUS, Mahl-
avu, SNU182) as "poorly-differentiated" HCC cell lines,
based on the lack of expression of both hepatocyte lineage
and epithelial cell markers analyzed here. In addition,
these poorly differentiated cell lines shared many features
with mesenchymal cells including the expression of mes-
enchymal markers (vimentin, slug, snail, twist-1, and
twist-2), high motility and invasiveness. These expression
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell lines Figure 2
Immunocytochemical analysis of mesenchymal marker vimentin protein in AFP+ and AFP- HCC cell lines. 
Cells grown on coverslips were subjected to immunoperoxidase assay using anti-vimentin antibody (brown), and counter-
stained with hematoxylin (blue).Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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and migratory features are associated with tumor dediffer-
entiation and confined to poorly differentiated HCCs [6-
8,14,34].
Expression TCF/LEF family of transcription factors
Following the identification of well-differentiated and
poorly differentiated HCC cell lines, we analyzed the
expression of 45 Wnt pathway genes by RT-PCR assay. We
first investigated the expression profile of TCF/LEF factors.
The TCF-1 and TCF-4 were highly expressed in all HCC
cell lines, while TCF-3 expression was limited to a subset
of cell lines (Figure 4). LEF-1 transcript expression was
weak, except for SNU398 cells. These findings indicated
that at least two different nuclear factors mediating canon-
ical Wnt signaling were expressed in any of HCC cell lines
tested.
Expression of Frizzled receptors and LRP co-receptors
Next we analyzed the expression of 10 Frizzled receptors
and their two co-receptors. Two canonical (Fzd1, Fzd5)
and three noncanonical (Fzd3, Fzd4, Fzd6) Frizzled recep-
tors were expressed in all cell lines tested. Also, Fzd2, Fzd7
and Fzd8 were expressed in most cell lines independent of
their differentiation status (Figure 5-top). Lrp-5 and Lrp-6
co-receptors also were consistently expressed in all cell
lines (Figure 5-bottom). These findings indicated that
HCC cell lines were equipped with the expression of sev-
eral canonical and noncanonial Wnt signaling receptors,
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motility Figure 3
Expression of hepatocyte lineage markers HNF-4 and HNF-1 in HCC cell line correlate with low motility. 
(a)Selective expression of HNF-4 and HNF-1 in AFP+ HCC cell lines. Total RNAs were extracted from cells and used for 
RT-PCR analysis of HNF-4 and HNF-1 expression. GAPDH RT-PCR was used as a loading control. (b. c) Differential motil-
ity of AFP+ and AFP- HCC cell lines. Cells were cultured in six-well culture plates, and a single linear wound was made with a 
pipette tip in confluent monolayer cells. The distances between wound edges were measured at fixed points in each dish 
according to standardized template. After 24 hours migration, cell migration into the wound was visualized using phase con-
trast microscopy at ×20 magnification (b). The number of cells migrating beyond the wound edge was counted (c). Assays in 
six replicates, error bars; SD. SNU475 cells are larger cells giving rise to visual overestimation of migrating cell number in the 
picture shown in b.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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so that each HCC cell line was likely to respond to both
canonical and noncanonical Wnt signals.
Differential expression of canonical and noncanonical 
Wnt ligands
In humans, there are 19 known genes encoding canonical
and noncanonical Wnt ligands [35]. We studied the
expression profile of the complete list of human Wnt lig-
ands (Figures 6 and 7). From the group of eight known
canonical Wnt ligands, only Wnt3 was strongly and uni-
formly expressed in all cell lines tested. Wnt10b was also
strongly expressed, but not in all cell lines (Figure 6). We
observed selective expression of canonical Wnt8b in well
differentiated cell lins. In contrast, among seven nonca-
nonical Wnt ligands, Wnt4, Wnt5a, Wnt5b and Wnt7b
were expressed in almost all poorly differentiated cell
lines tested. This contrasted with their poor expression in
well differentiated cell lines (Figure 7-top). Signaling spe-
cificity of four other Wnt ligands have not yet been clearly
established [35]. Among these ligands, Wnt9a expression
was detectable in nearly all cell lines tested. In contrast,
Wnt9b and Wnt2b expressions were associated to well dif-
ferentiated and poorly differentiated cell lines, respec-
tively (Figure 7-bottom).
Our comprehensive analysis of Wnt signaling molecules
in HCC cell lines revealed several features. First, with the
exception of Wnt ligands, most of the major components
of Wnt signaling pathway were expressed redundantly in
HCC cell lines, independent of their differentiation status.
In contrast, Wnt ligand expression displayed two types of
selectivity. First, out of eight known canonical only Wnt3
and Wnt10b displayed strong expression in most cell
lines, independent of differentiation status. Second, out of
seven noncanonical Wnt ligands, four were expressed in
HCC cell lines with a high selectivity for poorly differenti-
ated ones. Well-diffferentiated cell lines displayed selec-
tive expression of Wnt8b. These findings may have several
Table 1: Well-differentiated and poorly differentiated HCC cell lines according to hepatocyte lineage, epithelial and mesenchymal 
markers, and in vitro motility and invasiveness assays
Cell Lines Fetal 
Hepatocyte 
Marker
Epithelial & Hepatocyte 
Markers
Mesenchymal markers Motility Invasivene
ss
AFP HNF4a HNF1a E-cadherin vimentin slug Snail Twist-1 Twist-2
Well-
differentiated
HepG2 High High High Low (-) Low Low Low High Low Low [14]
Huh7 High High High High Low (±) Low Low (-) Low Low [14]
Hep3B High High High High Low High Low (-) (-) Low Low ([74]
Hep40 High High High Low High (-) High High Low Low n.t.
Poorly 
differentiated
SNU398 (-) (-) (-) Low High Low High High High Low n.t.
SNU475 (±) (-) (-) (-) High High High High Low High n.t.
SNU449 (-) Low (-) (±) High Low Low High High High n.t.
SNU387 (-) (-) (-) (-) Low High High (-) (±) n.t. n.t.
FOCUS (-) (-) (-) Low High Low (-) (-) Low n.t. n.t.
Mahlavu (-) (-) (-) (±) High Low (-) High Low High High [74]
SNU182 (-) (-) (±) High high High High High High High n.t.
(-); not detected; ±; traces; n.t.; not tested.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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implications. Most, in not all HCC cell lines were
equipped with an autocrine/paracrine canonical Wnt sig-
naling system, as reported previously for breast and ovar-
ian cancer cell lines [36]. In contrast, because of selective
expression of noncanonical Wnt ligands, only poorly dif-
ferentiated cell lines could serve from an autrocrine non-
canonical Wnt signaling system. In addition, poorly
differentiated HCC cells could also provide noncanonical
Wnt signals to other cells by a paracrine mechanism.
Finally, noncanonical Wnt ligands such as Wnt5a might
inhibit canonical Wnt signaling in HCC cells, as previ-
ously reported in other cell types [37-39].
Autocrine canonical Wnt signaling in well differentiated 
hepatocellular carcinoma cell lines
Canonical Wnt signaling activates TCF/LEF-dependent
transcription, which can be monitored by reporters con-
taining TCF/LEF-responsive elements [27,40]. We sur-
veyed canonical Wnt signaling in HCC cell lines using
TCF/LEF reporter pGL3-OT plasmid, as described previ-
ously [41]. First, we compared TCF/LEF (TCF) activity in
three cell lines with known mutations in canonical Wnt
signaling pathway (Figure 8a). Well-differentiated HepG2
cell line displays -catenin mutation. Poorly-differenti-
ated SNU398 and SNU475 cell lines display -catenin and
AXIN1 mutations, respectively [42,43]. Normalized TCF
activity was the highest in HepG2 cells. Compared to
HepG2, SNU398 cells displayed 50% less activity. More
interestingly, despite a homozygous deletion leading to a
loss of Axin1 expression (data not shown; [42,43], there
was no detectable TCF activity in SNU475 cells. This con-
trasted sharply with another well-differentiated AXIN1
mutant HCC cell line, namely PLC/PRF/5 (Alexander)
that displayed high TCF activity [42] (additional data not
shown).
Next, we compared TCF activity of eight other cell lines
that displayed wild-type -catenin and AXIN1 status [41-
43]. Hep40 cells that harbor a missense AXIN1 mutation/
polymorphism (R454H) was included in this group, since
functional significance of this mutation is unknown [41].
We detected weak, but significant (3-4 fold) TCF activity
in well-differentiated Huh7 and Hep3B cell lines. On the
other hand, all five poorly differentiated cell lines, as well
as well-differentiated Hep40 cells displayed no detectable
activity under our experimental conditions (Figure 8b).
Taken together, we collected TCF activity data from 12
HCC cell lines. Independent of -catenin or AXIN1 status,
TCF activity was detected in four out of five (80%) well-
differentiated cell lines, whereas only one out of seven
(14%) poorly differentiated cell lines had constitutive
TCF activity [P < 0.046 (one-tailed), 0.071(two-tailed);
Fisher Exact Probability Test]. This data supports the
hypothesis that well-differentiated HCC cells display an
autocrine/paracrine canonical Wnt signaling, probably
because they co-express Wnt3 and several canonical Friz-
zled receptors. However, the great majority of poorly dif-
ferentiated cell lines failed to generate canonical Wnt
signaling activity, although they similarly co-expressed
Wnt3 and canonical Frizzled receptors.
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell lines Figure 4
Comparative analysis of TCF/LEF transcription factors in hepatocellular carcinoma cell lines. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay of four members of TCF/LEF family. See Figure 
1 for GAPDH loading control.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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Canonical Wnt signaling is repressed in poorly 
differentiated hepatocellular carcinoma cells
The lack of canonical Wnt activity in poorly differentiated
cells could be due to either lack of sufficient Wnt ligand
activity. Alternatively, canonical Wnt signaling could be
repressed in these cell lines. A number of proteins down-
stream to -catenin such as Axin2, HTLE family, hAES,
Chibby, CTBP and ICAT are known to display inhibitory
activity on canonical Wnt signaling [44]. We compared
the expression of genes encoding these inhibitory pro-
teins, but found no correlation with TCF activity or differ-
entiation state (Figure 9).
Next, we compared TCF activity in Huh7, SNU449 and
SNU182 cell lines following transient expression of a
mutant (S33Y)--catenin (Figure 10). Transfection with
S33Y--catenin resulted in an increase in total -catenin
protein in Huh7 and SNU449. This increase was less evi-
dent in SNU182 cells (Figure 10a). Well-differentiated
Huh7 cells responded to S33Y--catenin expression by a
strong activation of TCF/LEF reporter (130 folds). Under
the same experimental conditions, the response of
SNU449 cells was minimal (5 folds). More importantly,
SNU182 cells were totally unresponsive (Figure 10b).
These important differences between well-differentiated
Huh7 and two different poorly differentiated cell lines
(SNU449 and SNU182) are apparently not due to differ-
ences in transient transfection efficiencies, since the meas-
ured activities have been corrected for such differences
(see material and methods section).
In order to confirm the data on weakened response in
poorly differentiated cell lines, we generated a clone from
SNU449 cells (SNU449-cl8) with Tet repressor controlled
expression of N-terminally truncated -catenin (aa 98-
781). N-terminally truncated -catenin forms are fre-
quently detected in cancer cells including HCC cells. They
lack Ser/Thr phosphorylation sites (aa Ser23, Ser29,
Ser33, Ser37, Thr41, Ser45) that are critically involved in
its ubiquitin-mediated degradation, and they accumulate
in the cell nucleus leading to oncogenic activation canon-
ical Wnt signaling [27]. As shown in figure 11a, SNU449-
cl8 cells expressed only wild-type -catenin in the pres-
ence of tetracycline (Tet-on conditions), while expressing
both wild-type and truncated -catenin at comparable lev-
els in Tet-off conditions. The induced expression of trun-
cated -catenin resulted in only a weak activation (3-4
fold) of TCF reporter activity, similar to data obtained by
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell lines Figure 5
Comparative analysis of Frizzled receptors and LRP co-receptors in hepatocellular carcinoma cell lines. Frizzled 
receptors involved in canonical and noncanonical Wnt signaling were tested for expression by RT-PCR assay (Top). The 
expression of LRP co-receptors was analyzed similarly (bottom). Total RNAs were extracted from cell lines and used to detect 
gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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transient transfection experiments (Figure 11b). This low
level of activation was similar to that seen in well-differen-
tiated HCC cells in the absence of -catenin or Axin-1
mutation (Fig. 8b), and strongly suggests that canonical
Wnt signaling is actively repressed in this poorly differen-
tiated HCC cell line. For comparison, well-differentiated
HepG2 cells expressing wild-type and a similar N-termi-
nally truncated -catenin (25-140 aa) activated TCF
reporter gene by more than 60-fold (Figure 8a). In other
words, although both Tet-off SNU449-cl8 and HepG2
cells displayed a heterozygous truncating -catenin muta-
tion, TCF activation was 15-fold less in poorly differenti-
ated SNU449 background. To test whether this repression
was related to cellular localization of -catenin, we per-
formed immunofluorescence detection using confocal
microscopy (Figure 11c). Wild-type -catenin was local-
ized at the cell membrane with weak nuclear localization.
The induction of truncated -catenin in Tet-off SNU449-
cl8 cells did not change this distribution significantly. We
observed only weak cytoplasmic accumulation, with
slight increases in both membrane and nuclear localiza-
tion. In sharp contrast with these observations, in colorec-
tal cancer cells (APC-mutated), used as a positive control
[45], we detected strong nuclear accumulation of -cat-
enin by the same technique.
WNT5A inhibits canonical Wnt signaling in HCC cells
Presently, the mechanism of repression of canonical Wnt
signaling in poorly differentiated HCC cells is unknown,
but it is associated with a lack of nuclear accumulation of
-catenin. Among noncanonical Wnt ligands, Wnt5a is
best known for its antagonistic effect on canonical Wnt
signaling [46]. Therefore, we tested the effect of ectopic
Wnt5a expression on mutant--catenin-induced TCF
activity in Huh7 cell line. In the absence of Wnt5a, TCF
activity was induced more than 160-fold by mutant -cat-
enin in this cell line. Co-expression of Wnt5a resulted in
three-fold repression of TCF activity (Figure 12a). To con-
firm our observations, we also tested the effects of Wnt5a
on TCF activity induced by endogenous mutant -catenin
using HepG2 cell line. The expression of Wnt5a in this cell
line caused a significant inhibition of TCF activation
mediated by endogenous -catenin (P < 0.05; Figure 12b).
We concluded that Wnt5a that is selectively expressed in
poorly differentiated HCC cell lines, and probably simi-
larly acting noncanonical Wnt ligands are involved, at
least partly, in the repression of canonical Wnt signaling
in these cells.
Discussion
Since the initial description of -catenin mutations in
HCCs in 1998 [33], Wnt signaling became a center of
interest for these tumors. A large set of Wnt ligands and a
large array of receptors are implicated in different cell
processes by initiating canonical, but also noncanonical
Wnt signals [35]. The antagonism between canonical and
noncanonical Wnt pathways has also been reported
[37,38,46]. Thus, both -catenin and Wnt signaling are
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell lines Figure 6
Comparative analysis of canonical Wnt ligands in hepatocellular carcinoma cell lines. Canonical Wnt ligands were 
tested for expression by RT-PCR assay. Total RNAs were extracted from cell lines and used to detect gene expression by RT-
PCR assay. See Figure 1 for GAPDH loading control.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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involved in highly complex cellular events of which only
some are mediated by canonical Wnt pathway. This com-
plexity is also observed during liver development and as
well as in adult liver homeostatic events. Canonical Wnt
signaling contributes to liver growth and regeneration,
but also to liver "zonation" by controlling some liver-spe-
cific metabolic programs. ([47]). In addition, it contrib-
utes to the activation of liver stem or progenitor cells, as
well as HCC-initiating cells [48-51].
Mutational activation of canonical Wnt signaling is not a
frequent event in HCC, in contrast to hepatoblastoma dis-
playing very high rates [52]. Mutations of -catenin were
restricted to a group of HCCs associated with low p53
mutation rate, negative HBV status and chromosomal sta-
bility, as stated earlier. These mutations were also associ-
ated with lower histological grade and better patient
survival. Unexpectedly, -catenin mutations are rare in
more advanced and poorly differentiated HCCs [20,23].
Therefore, although considered to play an active role in
HCC malignancy, the activation of canonical Wnt signal-
ing may not be necessary for, or even repressed in
advanced HCCs. Thus, -catenin mutation and constitu-
tive activation of canonical Wnt signaling may be differen-
tiation-dependent events with mechanistic implications
in HCC initiation and progression. We attempted to
address this issue by using HCC-derived cell lines.
We first classified 11 HCC cell lines into "well-differenti-
ated" and "poorly differentiated" subtypes using hepato-
cyte lineage, epithelial and mesenchymal cell markers,
and in vitro migration assays. Well-differentiated HCC
cell lines shared many features with hepatocytes such as
expression of HNF-1, HNF-4, and E-cadherin, and epi-
thelial morphology. Poorly differentiated cell lines were
usually deficient in the expression of hepatocyte lineage
and epithelial markers, but they expressed different mes-
enchymal markers strongly. These two types of HCC cell
lines were also distinguished from each other by their in
vitro behaviors. Poorly differentiated cell lines were usu-
ally more motile and more invasive than well-differenti-
ated cell lines (Table 1). A global expression profiling
study classified HCC cell lines in Group I and Group II
[51]. Our well-differentiated and poorly differentiated cell
line subtypes showed perfect correlation with Group I and
Group II, respectively. Well-differentiated Group I was
characterized by the activation of oncofetal promoters
leading to increased expression of AFP and IGF-II,
whereas poorly differentiated Group II was characterized
by overexpression of genes involved in metastasis and
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma cell lines Figure 7
Comparative analysis of noncanonical (top) and unclassified (bottom) Wnt ligands in hepatocellular carcinoma 
cell lines. Noncanonical and unclassified Wnt ligands were tested for expression by RT-PCR assay. Total RNAs were 
extracted from cell lines and used to detect gene expression by RT-PCR assay. See Figure 1 for GAPDH loading control.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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invasion. Our well-differentiated and poorly differenti-
ated subtypes were also in perfect correlation with respec-
tively epithelial and mesenchymal HCC cell line types
that have been identified very recently [12]. Mesenchymal
cancer cells are considered as the products of EMT that is
believed to be a key mechanism for the acquisition of
invasive and metastatic capabilities by tumor cells [53].
Higher motility of poorly differentiated HCC cell lines
reported here is in line with this concept. Thus, our two
classes of cell lines share many similarities with well-dif-
ferentiated and poorly differentiated HCC tumors. We
used this model to compare the status of Wnt pathway
according to HCC differentiation status.
A comprehensive analysis of Wnt signaling components
in liver or hepatocytes is lacking. However, the expression
of Wnt ligands and Frizzled receptors in mouse hepato-
cytes has been published [54]. Mouse hepatocytes
expressed canonical receptors Fzd7 and Fzd9, as well as
noncanonical Fzd2, Fzd3, Fzd4 and Fzd6. We observed
highly similar pattern of expression in HCC cell lines with
the exception of Fzd9 that showed weak expression. In
addition, we detected increased expression of canonical
Fzd1 and Fzd5 in most HCC cell lines. The expression fre-
quency of these receptors was not associated with HCC
cell differentiation status. Mouse hepatocytes expressed
canonical Wnt1 and Wnt2, and noncanonical Wnt4,
Wnt5a, Wnt5b and Wnt11. All or most HCC cell lines
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differentiated hepatocellular  carcinoma cell lines Figure 8
Frequent constitutive activation of canonical Wnt signaling in well-differentiated, but not in poorly differenti-
ated hepatocellular carcinoma cell lines. (a) Comparative analysis of the canonical Wnt signaling in hepatoma cell lines 
with known mutations of -catenin or Axin-1 genes. TCF reporter assay shows that well-differentiated HepG2 cells display 
high signaling activity. In contrast, canonical Wnt signaling is attenuated in poorly differentiated SNU398, and undetectable in 
poorly differentiated SNU475 cell line. Assays in triplicate, error bars; SD. (b) Comparative analysis of the canonical Wnt sign-
aling in HCC cell lines with wild-type -catenin and Axin-1 genes. Huh7 and Hep3B cell lines (both well-differentiated) display 
weak but significantly increased TCF reporter activity. Other cell lines (all poorly differentiated, except Hep40) display no 
detectable TCF reporter activity. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) and pGL3-OF (OF) 
plasmids, respectively. Assays in triplicate, error bars; S. D. Cells were transfected with the reporter gene pGL3-OT (OT) har-
boring LEF-1/TCF binding sites for -catenin and the corresponding pGL3-OF (OF) without these sites.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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have lost the expression of canonical Wnt1 and Wnt2, but
they displayed increased expression of canonical Wnt3
and Wnt10b ligands. Another canonical ligand, Wnt8b
was expressed selectively in well-differentiated cell lines.
In contrast, noncanonical Wnt4, Wnt5a and Wnt5b lig-
ands were expressed in the majority of poorly differenti-
ated cell lines, but not in most of well-differentiated cell
lines. In addition, most HCC cell lines (poorly differenti-
ated cell lines in particular) also displayed increased
expression of noncanonical Wnt7b. Among Wnt ligands
and Frizzled receptors that we found to be expressed or
upregulated in HCC cell lines, Wnt3, Wnt4, Wnt5a, Fzd3,
Fzd6 and Fzd7 have been previously reported to be over-
expressed also in primary HCC tumors [55-57]. Overex-
pression of Wnt10b was also reported in HCC cels [58].
Increased levels of Wnt5a transcripts were detected in
chronic hepatitis, cirrhosis and HCC [59]. A C-terminally
mutated HBV X protein was shown to upregulate Wnt5a
expression in HCC cells [60]. Thus, Wnt5a upregulation
observed in clinical samples might be related to HBV at
least in HBV-related liver diseases. Based on our observa-
tions that associate noncanonical Wnt ligand expression
to poorly differentiated HCC cell lines, it will be interest-
ing to test the predictive value of noncanonical Wnt
expression for HCC prognosis.
Another important finding of this study is the differential
activity of canonical Wnt signaling in different HCC sub-
types. Well-differentiated cell lines displayed active
canonical Wnt signaling at variable degrees. In addition to
strong signaling activity associated to -catenin and Axin1
mutations in two well differentiated cell lines, we also
observed autocrine canonical Wnt signaling in two other
well differentiated cell lines, as reported for some other
cancer cell lines [36]. The functional significance of auto-
crine canonical Wnt signaling in these cell lines is not
known.
However, small molecule antagonists of Tcf4/beta-catenin
complex were shown to inhibit TCF reporter activity and
down-regulate the endogenous Tcf4/-catenin target
genes c-Myc, cyclin D1, and survivin in Huh7 cells [61].
This observation strongly suggests that the autocrine
canonical Wnt signaling is functional in well-differenti-
ated HCC cell lines. Canonical Wnt signaling has been
linked to both stem cell and cancer cell self-renewal in
other cancer types. It was proposed that some adult can-
cers derive from stem/progenitor cells and that canonical
Wnt signaling in stem and progenitor cells can be sub-
verted in cancer cells to allow malignant proliferation
[62]. Indeed, well-differentiated-HCC cell lines identified
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cells Figure 9
Expression analysis of genes inhibiting canonical Wnt signaling downstream to -catenin in HCC cells. Total 
RNAs were extracted from cell lines and used to detect gene expression by RT-PCR assay. GAPDH RT-PCR was used as a 
loading control.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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here such as HepG2, Huh7 and PLC/PRF/5 have been
reported to harbor HCC stem cells [63]
Our third noteworthy observation was the lack of detecta-
ble canonical Wnt signaling activity in six out of seven
poorly differentiated cell lines. Even a poorly differenti-
ated cell line with a deleterious Axin1 mutation
(SNU475) lacked detectable signaling activity. Thus, most
probably, the canonical Wnt signaling was not only inac-
tive, but also repressed in poorly differentiated HCC cell
lines. In confirmation of this expectation, transient or Tet-
regulated expression of mutant -catenin failed to gener-
ate significant canonical Wnt signaling activity in two dif-
ferent poorly differentiated cell lines. Furthermore, we
linked this weak activity to poor nuclear accumulation of
-catenin protein in SNU449.cl8 cell line. Thus, unlike
well-differentiated cell lines, poorly differentiated HCC
cells displayed strong resistance to canonical Wnt signal
activation.
The mechanisms of resistance to canonical Wnt signal
activation in poorly differentiated HCC cells are presently
unknown. We provide here one potential mechanism.
Wnt5a has been previously implicated in canonical Wnt
signaling as an antagonist and regulator of -catenin lev-
els in other cell types [48,49]. Using both ectopic and
endogenous mutant -catenin expression systems in two
different cell lines, we demonstrated that co-transfections
with Wnt5a-expressing plasmid can significantly inhibit
canonical Wnt signaling in HCC cells. The mechanism of
Wnt5a antagonism on canonical Wnt signaling in HCC
cells is not known. In breast cancer cells, the loss of Wnt5a
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in poorly differenti- ated hepatocellular carcinoma cells Figure 10
Ectopic expression of mutant -catenin induces high canonical Wnt activity in well-differentiated, but not in 
poorly differentiated hepatocellular carcinoma cells. (a) Well-differentiated Huh7, and poorly differentiated SNU449 
and SNU182 cell lines have been co-transfected with either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) or 
empty pCI-neo plasmid (S33Y--catenin -), and cellular -catenin levels at post-transfection 48 h were tested by immunoblot-
ting. Calnexin was used as a loading control. (b) Cell lines were treated as described, then pCI-neo-mutant -catenin (S33Y)-
transfected cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals detected with pGL3-OT (OT) 
and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections included pGL-OT or pGL-OF, 
in addition to pCI-neo plasmids in both (a) and (b).Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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signaling resulted in stabilization of nuclear beta-catenin
and expression of Wnt/beta-catenin target genes [64].
However, both ectopically and endogenously expressed
mutant -catenins used in our experiments were N-termi-
nally truncated devoid of their Ser/Thr phosphorylation
motifs. Thus, Wnt5a appears to inhibit canonical Wnt sig-
naling in HCC cells, downstream to -catenin, independ-
ent of its glycogen synthase 3-- and bTrCO-dependent
degradation. Wnt5a has been shown to inhibit canonical
Wnt signaling either by bTrCP-independent proteasomal
degradation [65], or, by downregulating -catenin-
induced reporter gene expression without influencing -
catenin levels [37] in kidney epithelial cells. Wnt5a may
use similar mechanisms in Huh7 and HepG2 cells. Fur-
ther studies with downregulation of noncanonical Wnt
ligands in poorly differentiated HCC cell lines may help
to better define the implications of such ligands in liver
cancer biology.
The role of Wnt5a in cancer is complex. It may play
tumor-promoting or tumor-suppressing functions
depending on cellular context. Wnt5a has been described
as a tumor promoter in melanoma, gastric, pancreas, pros-
tate cancer, but as a tumor suppressor in HCC, neuroblas-
toma, leukemia, colon, and thyroid cancers [46]. The
inability of Wnt5a to transform cells or signal through the
canonical -catenin pathway pointed that it cannot pro-
mote tumorigenesis by upregulation of canonical Wnt sig-
naling, unlike canonical Wnt ligands [66]. Our results
suggest that Wnt5a, upregulated in poorly differentiated
highly motile mesenchymal-like HCC cells may play a
role in tumor progression by inducing EMT. Upregulation
of Wnt5a expression during EMT has been reported [67].
Furthermore, the Wnt5A/Protein kinase C pathway was
shown to mediate motility in melanoma cells via of an
EMT [68]. Similarly, CUTL1-upregulated Wnt5a signifi-
cantly enhanced migration, proliferation and invasiveness
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated SNU449 Figure 11
Minimal TCF reporter activity and lack of nuclear accumulation of mutant -catenin in poorly differentiated 
SNU449.cl8 cells. SNU449 cells were stably transfected with Tet-responsive N--catenin expression vector to obtain 
SNU448.cl8 cells. (a) Induced expression of N-terminally truncated N--catenin protein in the Tet-Off conditions, as tested 
by western blot assay. Total cell lysates were extracted from cells and subjected to western blot assay using anti--catenin anti-
body. (b) TCF activity is only weakly induced in Tet-off conditions, as tested by duplicate experiments. (c) SNU449.cl8 cells at 
Tet-On state express wild-type endogenous -catenin protein principally located at cell membrane. Under Tet-Off conditions 
the staining pattern remains almost identical despite N--catenin expression. Note lack of nuclear accumulation. SW480 cells 
used as positive control display strong nuclear -catenin staining. Cells were grown on coverslips, subjected to indirect immun-
ofluorescence assay using anti--catenin antibody (red), counterstained with DAPI (blue) and examined by confocal micros-
copy.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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in pancreas cancer cellls [69]. These effects were accompa-
nied by a marked modulation of marker genes associated
with EMT. Wnt5a may promote EMT in HCC cells by a
similar mechanism.
The expression status of Wnt5a in HCC is not well known.
To our knowledge, only one report addressed this issue
[59]. Compared to normal tissue, Wnt5a mRNA expres-
sion was strongly induced in HCC, as well as in chronic
hepatitis and cirrhosis. However, immunostaining of
Wnt5a protein showed a bell-shaped pattern: low to
undetectable levels were present in normal tissue and in
tumor samples, whereas strong immunostaining was seen
in chronic hepatitis, cirrhosis and dysplastic liver cells.
The reasons of the discrepancy between transcript and
protein expression in HCC tissues are not known pres-
ently. However, it appears that peritumoral liver tissues
express high levels of Wnt5a protein that could trigger
noncanonical Wnt signaling in adjacent tumor cells. It
will be important to further investigate the role of Wnt5a
in HCC tumor progression.
Taken together, our studies demonstrate that canonical
Wnt activity is active in well-differentiated, but repressed
in poorly differentiated HCC cell lines. This correlates
with in vivo tumor studies indicating that -catenin muta-
tions are prevelant in well-differentiated, but not in
poorly differentiated tumors. In addition, we showed that
poorly differentiated cell lines express noncanonical Wnt
ligands such as Wnt5a acting as an antagonist of canonical
Wnt signaling. Thus, it appears that HCC cells may acti-
vate or repress their canonical Wnt signaling, using auto-
crine/paracrine systems based on selective use of
canonical and noncanonical Wnt ligands.
We hypothesize that the active canonical Wnt signaling
observed in well-differentiated HCC cells contributes to
tumor initiation, but not necessarily to tumor progres-
sion. Instead, noncanonical Wnt signaling may be used by
poorly differentiated HCC tumors to promote cell motil-
ity and invasion. Selective use of canonical and nonca-
nonical Wnt signaling at different stages may be a key
mechanism involved in hepatocellular carcinogenesis.
Recent studies showed that canonical Wnt signaling con-
tributes to the self-renewal and expansion of HCC-initiat-
ing cells with stem/progenitor cell features [50,70].
However, the lack of HCC development in -catenin
transgenic mice strongly suggests that canonical Wnt sign-
aling activation has limited tumorigenic potential in liver
tissue. Indeed, recent studies showed that canonical Wnt
signaling plays a major role in the specification of mature
hepatocytes for perivenous-specific gene expression
([71,72]. Such a hepatocyte differentiation function of
canonical Wnt signaling may not be compatible with cel-
lular dedifferentiation that goes along with HCC develop-
ment. Therefore, alternative pathways such as Wnt5a-
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cells Figure 12
Wnt5a inhibits canonical Wnt signaling activity in Huh7 and HepG2 cells. (a) Huh7 cells were co-transfected with 
either pCI-neo-mutant -catenin (S33Y) plasmid (S33Y--catenin +) along with pShuttle-IRES-WNT5a or empty pShuttle-IRES 
vector. 48 hours post transfection; cells were subjected to TCF reporter assay. TCF activity denotes the ratio of signals 
detected with pGL3-OT (OT) and pGL3-OF (OF) plasmids, respectively. Assays in triplicate, error bars; SD. Co-transfections 
included pGL-OT or pGL-OF, in addition to pCI-neo-S33Y--catenin and pIRES plasmids. (b) HepG2 experiments were per-
formed under similar conditions, except that pCI-neo-mutant -catenin (S33Y) plasmid was omitted.Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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mediated noncanonical Wnt signaling may be necessary
for sustained growth and progression of HCC tumors.
Melanoma may serve as a demonstrated model to our
hypothesis. Similar to HCC, canonical Wnt signaling acti-
vation is an early event and nuclear -catenin accumula-
tion is associated with better patient survival in
melanoma. Nuclear -catenin is lost in more aggressive
melanomas that express Wnt5a that promotes EMT, cell
motility and metastasis[46]. Chien et al. [73] have
recently demonstrated that canonical Wnt signaling
induces growth inhibition and differentiation in
melanoma cells, whereas Wnt5a can antagonize some of
these effects. These findings clearly establish a dual func-
tion of Wnt signaling in melanoma. In light of these
recent developments, our findings call for further investi-
gations on respective roles of canonical and noncanonical
Wnt signaling in HCC.
Conclusion
Our observations support the hypothesis that Wnt path-
way is selectively activated or repressed depending on dif-
ferentiation status of HCC cells. We propose that
canonical and noncanonical Wnt pathways have comple-
mentary roles in HCC, where the canonical signaling con-
tributes to tumor initiation, and noncanonical signaling
to tumor progression.
Methods
Cell lines
Hepatocellular carcinoma cell lines Huh7, Hep40,
Hep3B, Hep3B-TR, FOCUS, Mahlavu, SNU182, SNU 387,
SNU 398, SNU423, SNU 449, SNU 475, PLC/PRF/5, SK-
Hep-1, hepatoblastoma cell line HepG2 and colorectal
cancer cell line SW480 were cultivated as described previ-
ously [41].
Reverse transcription-polymerase chain reaction (RT-
PCR) analysis
Total RNAs were extracted from cultured cells using
NucleoSpin RNA II Kit (MN Macherey-Nagel, Duren, Ger-
many) according to the manufacturer's protocol. The
cDNAs were prepared from total RNA (2 g) using Rever-
tAid First Strand cDNA Synthesis Kit (MBI-Fermentas, Vil-
nius, Lithuania). A negative control without reverse
transcriptase (1 l ddH2O instead) was also prepared for
each sample. All PCR reactions were carried out using 1 l
cDNA from the reverse transcription mix, for 35 cycles
except GAPDH, which was amplified for 24 cycles. Nega-
tive controls without reverse transcriptase were included
for each set of primers (primer sequence information is
available upon request). PCR products were analyzed on
a 2% (w/v) agarose gel.
Wound-healing assay
Cells were cultured in six-well culture plates in RPMI 1640
or DMEM with 10% FBS. A single linear wound was made
with a p200 pipette tip in confluent monolayer cells. The
distances between wound edges were measured at fixed
points in each dish according to standardized template.
Debris were removed by washing the cells twice with PBS
and then cells were incubated in RPMI 1640 or DMEM
with 2% FBS. After 24 hours migration, cells were fixed
with methanol and stained with 0.2% crystal violet. Cell
migration into the wound was visualized using phase con-
trast microscopy (x20 magnification). The number of cells
migrating beyond the wound edge was quantified micro-
scopically in the randomly selected fields for each tripli-
cate well.
Immunocytochemistry
Cells were grown on coverslips, fixed in 4% formalde-
hyde, permeated with 0.5% saponin/0.1% Triton X-100,
and stained with mouse monoclonal anti-human vimen-
tin antibody (Dako) using Envision kit (Dako), developed
with diaminobenzidine, and counterstained with hema-
toxylin.
Confocal microscopy
Cells were grown on slides in 6 well plates and were fixed
in 3.5% paraformaldehyde (PFA) for 15 minutes, and per-
mealized using 0,25% Triton-X-100 for 10 min. Non spe-
cific protein binding was blocked by 30 minutes of
incubation with 5% bovine serum albumin (BSA) in
phosphate-buffered saline (PBS) at room temperature.
Cells were then incubated 2 hours with monoclonal anti-
-catenin antibody M5.2 (1:200 dilution) in 1% BSA in
PBS at room temperature in a moist chamber. Immun-
ofluorescence staining was obtained by incubating for 1
hour with Alexa Fluor® 594 F(ab')2 fragment of rabbit
anti-mouse IgG (H+L) (Invitrogen) (dilution 1:750).
Cells were counterstained with DAPI (dilution 1:750),
slides were mounted using ProLong® Gold antifade rea-
gent (Invitrogen) and examined under Zeiss LSM 510
Meta laser scanning confocal microscope (MPI Freibourg,
Germany) using 488 nm and 543 nm laser excitation
lines, and photographed.
Plasmids
The pShuttle-IRES-Wnt5a expression plasmid was con-
structed by subcloning of an EcoRI-cut Wnt5a cDNA frag-
ment from plasmid pGEMTz-Wnt5a vector (a gift from R.
Kemler) into BglII site of the pShuttle-IRES-hrGFP-1 vec-
tor (Stratagene, USA). pCI-Neo-mutant -catenin (S33Y)
expression plasmid, and pGL3-OT and pGL3-OF reporter
plasmids were kindly provided by B. Vogelstein. Other
plasmids were pCI-Neo (Promega) and pEGFP-N2 (Clon-
tech, Palo Alto, CA). The pAUCT-N--catenin plasmid
expressing N-terminally truncated -catenin (aa 98-781)Molecular Cancer 2009, 8:90 http://www.molecular-cancer.com/content/8/1/90
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under the control of Tet repressor was constructed using
pAUCT-CCW vector (gift from Ali Fattaey, USA). A cDNA
fragment of XhoI-NotI digestion from pCI-Neo-mutant -
catenin (S33Y) plasmid was inserted into XhoI-NotI site
of pAUCT-CCW vector.
Transfections
Endogenous TCF/LEF-dependent transcriptional activity
was tested by using pGL3-OT and pGL3-OF reporter plas-
mids, as described previously [41], except that cells were
transfected using Lipofectamin 2000 reagent (Invitrogen),
following instructions provide by the supplier. Mutant -
catenin-induced TCF/LEF-dependent transcriptional
activity was tested after co-transfection of cells with pCI-
Neo-mutant -catenin (S33Y) expression plasmid (1.75
g/well) together with the reporter plasmids. pCI-Neo
(1.75 g/well) was used as negative control. The effect of
Wnt5a expression on TCF/LEF-dependent transcriptional
activity was tested using Huh7 and HepG2 cell lines.
Huh7 cell line was co-transfected with pCI-Neo-mutant -
catenin (S33Y) expression plasmid (1 g/well) together
with either pShuttle-IRES-Wnt5a (0.75 g/well) or the
empty vector pShuttle-IRES-hrGFP-1 (0.75 g/well) and
pGL3-OT/pGL3-OF reporter plasmids (0.75 g/well for
each). At 48 h following transfection, luciferase assay was
performed by using Luciferase Reporter Gene Assay, con-
stant light signal kit (Roche Diagnostics GmbH., Man-
nheim, Germany). Luciferase activity was read with The
Reporter® Microplate Luminometer (Turner BioSystems
Inc., Sunnyvale, CA) and data was normalized according
to transfection efficiency obtained with each transfection,
as described previously [41]. HepG2 cell line was co-trans-
fected with either pShuttle-IRES-Wnt5a (0.5 g/well) or
the empty vector pShuttle-IRES-hrGFP-1 (0.5 g/well)
and pGL3-OT/pGL3-OF reporter plasmids (0.5 g/well
for each), with an internal control (0.05 g/well pRL-TK
Renilla luciferase vector) in a 12-well plate, using Lipo-
fectamine 2000 Transfection Reagent. Forty-eight hours
post-transfection, the cells were washed with PBS, and
lysed in passive lysis buffer (Dual Luciferase kit;
Promega). The cell lysates were transferred into an Opti-
Plate 96-well plate (Perkin-Elmer) and assayed in a 1420-
Multilabel counter luminometer, VICTOR3 (Perkin-
Elmer) using the Dual-Luciferase kit (Promega). Relative
TOP-FLASH luciferase units were measured and normal-
ized against Renilla luciferase activity and further normal-
ized luciferase activity against FOP-FLASH activity. All
transfection experiments were performed in triplicate and
data were expressed as mean of triplicate values (±S. D.)
and p values were calculated. TCF/LEF activity was
reported as the ratio of normalized luciferase activities
obtained with pGL-OT and pGL-OF plasmids, respectively
(mean ± S. D.).
Generation of mutant -catenin expressing SNU449-cl8 
cell line
SNU449 cell line clone ectopically expressing N-termi-
nally truncated (aa 98-781) -catenin, under the control
of Tet repressor was generated by stable transfection with
pAUCT-N--catenin plasmid. Briefly, SNU449 cells were
plated onto 6-well plate and transfected with 2 g of plas-
mid DNA using Lipofectamin 2000 reagent (Invitrogen).
24 hours post transfection, cells were transferred to 90
mm dishes and subjected to G418 (0.6 g/ml) selection in
the presence of tetracycline (1 g/ml) until resistant cell
colonies became visible. Several clones were tested by
Western blot for the expression of N-terminally truncated
(aa 98-781) -catenin after withdrawing tetracycline from
the culture medium to induce the expression of the trans-
gene. Only one clone (SNU449-cl8) displayed Tet-
dependent expression of mutant -catenin, and it was
used for further studies.
Western blotting
Detergent-soluble cell lysates were prepared at 48 h post-
transfection and used for western blot analysis, as
described previously [41]. Antibodies to -catenin (Santa
Cruz Biotechnology, Inc., CA) and calnexin (Sigma) were
obtained commercially. ECL kit (Amersham Life Science,
Inc., Piscataway, NJ) was used for detection of antigen-
antibody complexes. Equal protein loading was verified
by Western blot assay with calnexin antibody.
Statistical analysis
The statistical significance of the active TCF reporter activ-
ity between well-differentiated and poorly differentiated
HCC cell lines was tested by Fisher Exact Probability Test
using an on-line tool http://faculty.vassar.edu/lowry/Vas
sarStats.html.
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